Evidence map›Paper›PMID 22575858›Full record

ReviewAdvanced drug delivery reviews2012

Microneedles for drug and vaccine delivery.

Yeu-Chun Kim, Jung-Hwan Park, Mark R Prausnitz

Registry-linked trialAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Advanced drug delivery reviews, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05078463 (Transdermal Microneedle Patch To Enhance Topical Anaesthesia Before Intravenous Line Insertion for Blood Transfusion In Paediatric Thalassemia Patients), which is not on this map. Cited by 548 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
548citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05078463 phase2completednot on this mapstarted 2021, after this paper: background citation

Transdermal Microneedle Patch To Enhance Topical Anaesthesia Before Intravenous Line Insertion for Blood Transfusion In Paediatric Thalassemia Patients

TypeinterventionalSponsorUniversiti Kebangsaan Malaysia Medical CentreRan2021 to 2022Enrolled20ConditionsThalassemia in ChildrenArmsMicroneedle, 1 Finger Tip Unit (FTU) EMLA Cream (30-minute application time), 1 Finger Tip Unit (FTU) EMLA (15-minute application time), 0.5 Finger Tip Unit (FTU) EMLA (30-minute application time), Sham Patch
3 · Its place in the literature

Who cites it

548 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review

488 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Yeu-Chun KimDepartment of Chemical and Biomolecular Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, Republic of Korea. dohnanyi@kaist.ac.kr
Jung-Hwan Park
Mark R Prausnitz

Funding

Influenza vaccination using a microneedle patchU01EB012495 · NIBIB · GEORGIA INSTITUTE OF TECHNOLOGY · PI PRAUSNITZ, MARK R. · 2010 to 2015
$9.6M
Microneedle-based immunization against pandemic influenzaR01EB006369 · NIBIB · GEORGIA INSTITUTE OF TECHNOLOGY · PI PRAUSNITZ, MARK R. · 2007 to 2011
$3.6M
NIBIB NIH HHS R01 EB006369NIBIB NIH HHS U01 EB012495
6 · The paper itself

Abstract

Microneedles were first conceptualized for drug delivery many decades ago, but only became the subject of significant research starting in the mid-1990's when microfabrication technology enabled their manufacture as (i) solid microneedles for skin pretreatment to increase skin permeability, (ii) microneedles coated with drug that dissolves off in the skin, (iii) polymer microneedles that encapsulate drug and fully dissolve in the skin and (iv) hollow microneedles for drug infusion into the skin. As shown in more than 350 papers now published in the field, microneedles have been used to deliver a broad range of different low molecular weight drugs, biotherapeutics and vaccines, including published human studies with a number of small-molecule and protein drugs and vaccines. Influenza vaccination using a hollow microneedle is in widespread clinical use and a number of solid microneedle products are sold for cosmetic purposes. In addition to applications in the skin, microneedles have also been adapted for delivery of bioactives into the eye and into cells. Successful application of microneedles depends on device function that facilitates microneedle insertion and possible infusion into skin, skin recovery after microneedle removal, and drug stability during manufacturing, storage and delivery, and on patient outcomes, including lack of pain, skin irritation and skin infection, in addition to drug efficacy and safety. Building off a strong technology base and multiple demonstrations of successful drug delivery, microneedles are poised to advance further into clinical practice to enable better pharmaceutical therapies, vaccination and other applications.

Indexed as

NeedlesAnimalsDrug Delivery SystemsHumansMicroinjectionsMicrotechnologyPharmaceutical PreparationsVaccinesPharmaceutical PreparationsVaccines

Identifiers

PMID22575858
PMCPMC3419303

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.